Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 13, 2007

Grant Life Sciences Gains HPV DNA-based Test from Alphagenics

  • Grant Life Sciences has licensed the manufacturing and marketing rights to Alphagenics Diaco Biotechnologies’ molecular diagnostic test for HPVs. This HPV test is a DNA-based molecular diagnostic that uses standard equipment found in most commercial laboratories.

    The Memo of Understanding between the companies gives Grant Life Sciences exclusive rights in Greater China and the U.S. and nonexclusive rights in Europe, India, Australia, and Japan. 

    Alphagenics' HPV DNA test complements the HPV blood test that Grant Life Sciences has been developing. The blood test is a serum-based immunological test to detect cervical dysplasia.

    While a serum-based test to detect precancerous evidence and cancer of the cervix is still viewed by Grant Life Sciences as the preferred test-methodology to address the needs of the developing world, molecular testing is currently the approved test protocol in both the U.S. and Europe. Grant expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the fourth quarter of this year.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »